Long-Term Outcomes with Filgotinib, an Oral Preferential Janus Kinase 1 Inhibitor: 100-Week Data from an Open-Label Extension (OLE) Study in Patients with PSA

Coates, LC, Gladman, DD, Van den Bosch, F et al. (10 more authors) (2021) Long-Term Outcomes with Filgotinib, an Oral Preferential Janus Kinase 1 Inhibitor: 100-Week Data from an Open-Label Extension (OLE) Study in Patients with PSA. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.